Evelo Biosciences

54 articles with Evelo Biosciences

• Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

  4/5/2021

  Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th 2:15 p.m. ET.

• Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People

  3/23/2021

  Collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel Health’s first biotechnology licensing agreement

• Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

  3/9/2021

  –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021– –Up to 8 clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET–

• Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

  3/2/2021

  Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021 to report its fourth quarter and full year 2020 financial results and discuss business highlights.

• 

  BioSpace Movers & Shakers, Feb. 19

  2/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors

  2/16/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of John Hohneker, M.D., to its Board of Directors.

• Evelo Biosciences Announces Pricing of Public Offering of Common Stock - Jan 29, 2021

  1/29/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock, at a public offering price of $15.00 per share, before underwriting discounts and commissions.

• Evelo Biosciences Announces Proposed Public Offering of Common Stock - Jan 28, 2021

  1/28/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering.

• 

  Clinical Catch-Up: January 18-22

  1/25/2021

  With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.

• Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis

  1/20/2021

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced new positive confirmatory data following completion of the mild and moderate atopic dermatitis cohort in its Phase 1b clinical trial.

• Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones

  1/7/2021

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced its strategic priorities and anticipated milestones for 2021.

• Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer

  12/21/2020

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced the appointment of Jonathan Zung, Ph.D., as Chief Development Officer and a member of the Evelo Executive Team.

• Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis

  12/9/2020

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine with systemic effects, today announced positive topline clinical data from its Phase 1b clinical trial of EDP1815 in 23 evaluable subjects with mild to moderate atopic dermatitis.

• Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer

  12/9/2020

  –EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503– –Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity–

• Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis

  12/3/2020

  Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced that it is recruiting ahead of schedule and has completed enrollment of the patients necessary for the interim data readout in the Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis

• Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting

  11/9/2020

  Evelo Biosciences, Inc.today announced preclinical data for EDP1908, its extracellular vesicle product candidate for the treatment of cancer, in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting.

• Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights

  10/29/2020

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the third quarter of 2020.

• Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

  10/22/2020

  Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and business highlights.

• 

  Clinical Catch-Up: October 12-16

  10/19/2020

  It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.

• Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for EDP1815

  10/15/2020

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that it will host a key opinion leader discussion on the unmet need in psoriasis and atopic dermatitis, including the potential of EDP1815 to serve as a new therapeutic option for patients living with mild to moderate disease.